Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular-Based Techniques Diagnose Leprosy

By LabMedica International staff writers
Posted on 23 Apr 2014
The classic tools to diagnose leprosy are based on bacillary counts and histopathology, but these have been facing hurdles, especially in distinguishing latent infection from active disease and diagnosing paucibacillary clinical forms.

Serological tests and interferon gamma (IFN-γ) releasing assays (IGRA) that employ humoral and cellular immune parameters, respectively, are also being used, but recent results indicate that quantitative polymerase chain reaction (qPCR) is a key technique due to its higher sensitivity and specificity.

Scientists at the Instituto Oswaldo Cruz (Rio de Janeiro, Brazil) have evaluated the various molecular assays now being used to detect Mycobacterium leprae, the causative agent of leprosy. More...
Advances concerning the structure and function of the M. leprae genome led to the development of specific PCR-based gene amplification assays for leprosy diagnosis and monitoring of household contacts.

Some of their findings suggest that commercial kits can be used to extract, purify and amplify M. leprae DNA, ribonucleic acid (RNA), or both. Samples can also be easily stored in 70% ethanol and fast technology for analysis of nucleic acids (FTA) cards (Whatman, Maidstone, UK) for M. leprae DNA detection. Irrespective of whether the detection method used is conventional or real-time PCR, smaller PCR products allow for better amplification efficiency from DNA extracted from either formalin- or ethanol-fixed or fresh tissues. In fact, an important advance has been the real-time PCR technology.

While PCR diagnosis is not needed for lepromatous patients with high bacillary load and high number of lesions, it is extremely helpful for the diagnosis of the situations such as clinical presentations with scarce number of M. leprae bacilli (paucibacillary) and difficult-to-diagnose patients. The detection of M. leprae DNA in different samples of the household contacts of leprosy patients is very promising. Although a positive PCR result is not sufficient to establish a causal relationship with disease outcome, quantitation provided by qPCR is clearly capable of indicating increased risk of developing the disease and could alert clinicians to follow these contacts more closely or even define rules for chemoprophylaxis.

The authors concluded that overall, extensive evaluation of PCR tests in field studies has shown that DNA-based PCR assays can be 100% specific, while the sensitivity ranges from 34% to 80% in patients with paucibacillary forms to greater than 90% in patients with multibacillary forms of the disease. PCR has been ascertained to be especially valuable in diagnosing difficult cases like pure neural leprosy, paucibacillary, and patients with atypical clinical presentation and histopathological features compatible with leprosy. The study was published on April 10, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Instituto Oswaldo Cruz
Whatman 

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.